



RECEIVED

MAR 07 2003

Corres. and Mail

BOX AF

S&amp;H Form: (01/03)

TECH CENTER 1600/2000

REPLY/AMENDMENT  
FEE TRANSMITTAL

Attorney Docket No.	1546.1007
Application Number	09/995,829
Filing Date	November 29, 2001
First Named Inventor	Ji-Won YOON, et al.
Group Art Unit	1648
Examiner Name	Myron G. Hill

AMOUNT ENCLOSED

410.00

## FEE CALCULATION (fees effective 01/01/03)

CLAIMS AS AMENDED	Claims Remaining After Amendment	Highest Number Previously Paid For	Number Extra	Rate	Calculations
TOTAL CLAIMS	5	- 20 =	0	X \$ 18.00 =	\$ 0.00
INDEPENDENT CLAIMS	1	- 3 =	0	X \$ 84.00 =	0.00
Since an Official Action set an original due date of <u>March 1, 2003</u> (filed <u>March 3, 2003</u> as <u>March 1, 2003</u> is a <u>Saturday</u> ), petition is hereby made for an extension to cover the date this reply is filed for which the requisite fee is enclosed (1 month (\$110);					410.00
If Notice of Appeal is enclosed, add (\$320)					
If Statutory Disclaimer under Rule 20(d) is enclosed, add fee (\$110)					\$ 410.00
Total of above Calculations =					
Reduction by 50% for filing by small entity (37 CFR 1.9, 1.27 & 1.28)					\$ 410.00
TOTAL FEES DUE =					
(1) If entry (1) is less than entry (2), entry (3) is "0".					
(2) If entry (2) is less than 20, change entry (2) to "20".					
(4) If entry (4) is less than entry (5), entry (6) is "0".					
(5) If entry (5) is less than 3, change entry (5) to "3".					

## METHOD OF PAYMENT

- ☒ Check enclosed as payment.
- ☐ Charge "TOTAL FEES DUE" to the Deposit Account No. below.
- ☐ No payment is enclosed and no charges to the Deposit Account are authorized at this time (unless specifically required to obtain a filing date).

## GENERAL AUTHORIZATION

- ☒ If the above-noted "AMOUNT ENCLOSED" is not correct, the Commissioner is hereby authorized to credit any overpayment or charge any additional fees necessary to:
- Deposit Account No. 19-3935
- Deposit Account Name STAAS & HALSEY LLP
- ☒ The Commissioner is also authorized to credit any overpayments or charge any additional fees required under 37 CFR 1.16 (filing fees) or 37 CFR 1.17 (processing fees) during the prosecution of this application, including any related application(s) claiming benefit hereof pursuant to 35 USC § 120 (e.g., continuations/divisionals/CIPs under 37 CFR 1.53(b) and/or continuations/divisionals/CPAs under 37 CFR 1.53(d)) to maintain pendency hereof or of any such related application.

SUBMITTED BY: STAAS &amp; HALSEY LLP

Typed Name Michael D. Stein

Reg. No. 37,240

Signature

Date

3/3/03

©2001 Staas &amp; Halsey LLP



RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1648  
Docket No.: 1546.1007

#10  
Ext (mos)  
3/11/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Ji-Won YOON, et al.

Serial No. 09/995,829

Group Art Unit: 1648

RECEIVED

MAR 07 2003

Confirmation No. 9726

TECH-CENTER 1600/2900

Filed: November 29, 2001

Examiner: Myron G. Hill

For: PREVENTION OF AUTOIMMUNE DIABETES BY IMMUNOGENE THERAPY USING  
RECOMBINANT VACCINIA VIRUS EXPRESSING GLUTAMIC ACID  
DECARBOXYLASE (As Amended)

AMENDMENT UNDER 37 C.F.R. 1.116(b)

Assistant Commissioner for Patents  
Washington, D.C. 20231

Attention: **BOX AF**

Dear Sir:

This is in response to the Office Action mailed October 1, 2002, and having a period for response set to expire on January 1, 2003. A Petition for a two-month extension of time, together with the requisite fee for same, is submitted herewith, thereby extending the period for response to March 1, 2003 (filed March 3, 2003 as March 1, 2003 is a Saturday).

The following amendments and remarks are respectfully submitted. Reconsideration of the claims is respectfully requested.

IN THE TITLE:

Please DELETE the Title in its entirety and substitute the NEW Title as follows:

--PREVENTION OF AUTOIMMUNE DIABETES BY IMMUNOGENE THERAPY USING  
RECOMBINANT VACCINIA VIRUS EXPRESSING GLUTAMIC ACID DECARBOXYLASE--

03/05/2003 MBLANCO 00000008 09995829

01 FC:1252

410.00 OP

WJ 3/11/03  
OK to  
enter  
B1